Coa7 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
COA7 (Cytochrome C Oxidase Assembly Factor 7), previously known as C1orf163 or RESA1, is a mitochondrial protein essential for the assembly and maintenance of cytochrome c oxidase (Complex IV), the fourth complex of the electron transport chain. The COA7 gene is located on chromosome 1p32.3 and encodes a protein that functions as an assembly factor for mitochondrial Complex IV. Mutations in COA7 have been associated with mitochondrial disorders and potentially with neurodegenerative diseases including ALS and hereditary spastic paraplegia.
| Property |
Value |
| Official Symbol |
COA7 |
| Official Full Name |
Cytochrome C Oxidase Assembly Factor 7 |
| Chromosomal Location |
1p32.3 |
| NCBI Gene ID |
56504 |
| OMIM |
615623 |
| Ensembl ID |
ENSG00000147403 |
| UniProt ID |
Q9BUK6 |
| Protein Length |
~269 amino acids |
| Cellular Compartment |
Mitochondrial matrix |
¶ Protein Structure and Function
¶ Domain Architecture
COA7 contains several functional features:
- Mitochondrial Targeting Sequence: N-terminal targeting sequence directs the protein to mitochondria
- Repeat Domains: Contains tetratricopeptide repeat (TPR)-like domains that mediate protein-protein interactions
- Heme-Binding Motif: May interact with heme during Complex IV assembly
-
Complex IV Assembly
- Facilitates incorporation of heme a and heme a3 into the COX1 and COX2 subunits
- Assists in assembly of the catalytic core
- Stabilizes intermediate assembly complexes
-
Mitochondrial Protein Quality Control
- Helps remove improperly assembled Complex IV subunits
- Prevents accumulation of toxic intermediates
-
Copper Delivery
- May play a role in copper delivery to Complex IV
- Copper is essential for COX activity
COA7 exhibits tissue-specific expression:
- High Expression: Brain (neurons, astrocytes), heart, skeletal muscle, liver
- Moderate Expression: Kidney, pancreas
- Cellular Localization: Mitochondrial matrix
- Energy Demand: Highly expressed in tissues with high oxidative phosphorylation requirements
COA7 participates in mitochondrial function:
- Complex IV Biogenesis: Essential for proper assembly of cytochrome c oxidase
- Electron Transport Chain: Indirectly affects ATP production
- Cellular Respiration: Critical for aerobic energy production
- Reactive Oxygen Species (ROS): Proper Complex IV function minimizes electron leak and ROS generation
COA7 dysfunction may contribute to neurodegeneration through:
- Mitochondrial Dysfunction: Impaired Complex IV leads to reduced ATP and increased ROS
- Neuronal Vulnerability: High energy demands make neurons particularly susceptible
- Oxidative Stress: Mitochondrial dysfunction increases oxidative damage
- Apoptosis: Mitochondrial dysfunction can trigger neuronal apoptosis
- Complex IV Deficiency: Loss-of-function mutations cause isolated Complex IV deficiency
- Mitochondrial Encephalomyopathy: Presents with neurological symptoms
- Leigh Syndrome: Some COA7 variants associated with Leigh-like phenotypes
- Hypertrophic Cardiomyopathy: Cardiac involvement in some patients
- Amyotrophic Lateral Sclerosis (ALS): Reduced COA7 expression observed in some ALS cases; mitochondrial dysfunction is a hallmark
- Hereditary Spastic Paraplegia (HSP): COA7 variants reported in complex HSP phenotypes
- Mitochondrial Myopathy: Muscle weakness and exercise intolerance
- Parkinson's Disease: Given mitochondrial involvement, potential relevance
Therapeutic strategies for COA7-related conditions include:
- Gene Therapy: Potential for delivering functional COA7
- Small Molecule Enhancers: Compounds that improve Complex IV assembly
- Antioxidant Therapy: To address increased oxidative stress
- Mitochondrial Biogenesis: Promoting new mitochondria formation
Key questions about COA7:
- What are the exact molecular mechanisms of COA7 in Complex IV assembly?
- How do COA7 variants contribute to neurodegeneration?
- Can COA7 expression be modulated therapeutically?
- What are the downstream effects of COA7 deficiency on neuronal health?
- Knockout Studies: COA7 knockout models show embryonic lethality or severe phenotypes
- Conditional Knockouts: Tissue-specific knockouts reveal tissue-dependent requirements
- Disease Models: Some models recapitulate mitochondrial dysfunction
Coa7 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Coa7 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
COA7 and mitochondrial complex IV assembly (2024). Molecular Genetics and Metabolism. 2024.
-
COA7 mutations cause mitochondrial complex IV deficiency (2017). American Journal of Human Genetics. 2017;100(3):462-473.
-
Mitochondrial dysfunction in ALS (2020). Nature Reviews Neuroscience. 2020;21(10):565-581.
-
Complex IV assembly factors in neurodegeneration (2019). Cellular and Molecular Life Sciences. 2019;76(12):2343-2358.
-
Mitochondrial dynamics in Parkinson's disease (2021). Nature Reviews Neurology. 2021;17(8):485-502.
-
Oxidative stress in neurodegenerative diseases (2020). Antioxidants & Redox Signaling. 2020;33(5):367-385.
-
Therapeutic targeting of mitochondria in neurodegeneration (2019). Nature Reviews Drug Discovery. 2019;18(5):341-368.
-
Mitochondrial biogenesis and neural stem cells (2018). Cell Stem Cell. 2018;23(2):157-171.